A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

NCT06341556 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma
Maintenance Therapy

Interventions

DRUG: Zanubrutinib

Sponsor

Fudan University